Teduglutide (Gattex / Revestive)
Teduglutide (rDNA origin); [Gly2]-GLP-2(1-33); recombinant analog of human glucagon-like peptide-2 (GLP-2); marketed as GATTEX (US/Takeda) and Revestive (EU/Takeda)
Approved status applies to specific products, routes, and indications, not every use context discussed online.
An FDA-approved injection (Gattex in the US, Revestive in Europe) for adults and children as young as 1 year old with short bowel syndrome who depend on IV nutrition. It helps the remaining intestine grow and absorb more nutrients, potentially reducing or eliminating the need for IV feeding. In the main clinical trial, 46% of patients significantly reduced their IV nutrition needs compared to 6% on placebo.
Safety Summary
Most common adverse effects are gastrointestinal (abdominal pain, nausea, distension, vomiting) and are generally mild to moderate in severity, often decreasing over time. Note: Side effect frequencies vary between FDA label Table 1 (Studies 1 and 3, N=77 GATTEX vs N=59 placebo) and broader pooled safety data (n=566). Both sets of frequencies are reported above where they differ. Key safety monitoring requirements: (1) Colonoscopy/endoscopy at baseline (within 6 months) and yearly/5-yearly to detect polyps (GI neoplasia warning), (2) bilirubin/ALP/lipase/amylase labs every 6 months for biliary/pancreatic disease, (3) fluid status monitoring especially in patients with cardiovascular disease. In patients with stoma, 42% experienced GI stoma complications vs 14% placebo. A case of coma was reported in a patient taking concurrent benzodiazepines (prazepam) due to increased intestinal absorption of the oral medication (prazepam blood level >300 mcg/L). Enhanced absorption may affect any concomitant oral medication, particularly those with narrow therapeutic indices. Anti-drug antibodies were cross-reactive to native GLP-2 in 83% of tested antibody-positive patients, but mostly non-neutralizing with no clinically relevant impact on safety or efficacy. Antibody titers declined with continued therapy. Pediatric safety profile was similar to adults. Long-term safety data (up to 5 years in registries/extensions) showed AEs mostly mild-moderate, decreasing over time, with no new CRC cases despite increased polyp detection. FAERS database analysis confirmed known safety signals and identified disproportional signals for nephrolithiasis, dehydration, and renal AEs, but no cancer signal above background.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-13]